657424-77-6

Upstream product

• 57961-48-5 ethyl 4-(3-chlorophenyl)-2,4-dioxobutanoate 
• 99-02-5 3'-Chloroacetophenone 
• 120121-01-9 1-(m-Chlorophenyl)ethanol 
• 587-04-2 m-Chlorobenzaldehyde 
• 95080-93-6 ethyl chlorooximidoacetate 
• 766-83-6 m-chlorophenylacetylene 
• 67-56-1 methanol 
• 14337-43-0 ethyl 2-chloro-2-(hydroxyimino)acetate 

Downstream Products

• 657424-79-8 [5-(3-Chloro-phenyl)-isoxazol-3-yl]-methanol 
• 657424-83-4 1-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-ethanone 
• 1188200-46-5 C₁₂H₉BrClNO₃ 
• 1273029-86-9 C₁₅H₁₄BrClN₂O₂ 
• 925940-95-0 5-(3-chloro-phenyl)-isoxazole-3-carboxylic acid 
• 1018681-04-3 2-benzyloxy-4-(5-{1-[5-(3-chloro-phenyl)-isoxazol-3-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine 
• 1018680-68-6 4-(5-{1-[5-(3-chloro-phenyl)-isoxazol-3-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-1H-pyridin-2-one 
• 1018680-64-2 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)-1-methylpyridin-2(1H)-one 
• 934282-59-4 (1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethyl acetate 
• 934282-60-7 (R)-1-[5-(3-chloro-phenyl)-isoxazol-3-yl]-ethanol 
• 657427-36-6 1-[5-(3-chlorophenyl)isoxazol-3-yl]ethanol 
• 1277100-16-9 C₂₃H₂₄ClN₅O₃*ClH 

Relevant academic research and scientific papers

Design and synthesis of novel 5-arylisoxazole-1,3,4-thiadiazole hybrids as α-glucosidase inhibitors

Background: α-Glucosidase inhibitors have occupied a significant position in the treatment of type 2 diabetes. In this respect, the development of novel and efficient non-sugar-based inhibitors is in high demand. Objective: Design and synthesis of new 5-arylisoxazole-1,3,4-thiadiazole hybrids possessing α-glucosidase inhibitory activity were developed. Methods: Different derivatives were synthesized by the reaction of various 5-arylisoxazole-3-carboxylic acids and ethyl 2-((5-amino-1,3,4-thiadiazol-2-yl)thio)acetate. Finally, they were evalu-ated for their α-glucosidase inhibitory activity. Results: It was found that ethyl 2-((5-(5-(2-chlorophenyl)isoxazole-3-carboxamido)-1,3,4-thiadiazol-2-yl)thio)acetate (5j) was the most potent compound (IC50 = 180.1 μM) compared with acarbose as the reference drug (IC50 = 750.0 μM). Also, the kinetic study of 5j revealed a competitive inhibition and docking study results indicated desired interactions of that compound with amino acid residues located close to the active site of α-glucosidase. Conclusion: Good α-glucosidase inhibitory activity obtained by the title compounds introduced them as an efficient scaffold, which merits to be considered in anti-diabetic drug discovery developments.

Functionalized β,β-dichloroenones and β,β-dibromoenones as versatile building blocks: Synthesis and transformations

An efficient one-step synthesis of functionalized β,β-dichloroenones and β,β-dibromoenones was achieved via the Fe-catalyzed radical induced reaction between silyl enol ethers and carbon tetrachloride, bromotrichloromethane or carbon tetrabromide in moderate to good yields. This reaction proceeds through addition of the trichloromethyl or tribromomethyl radical group to the C[dbnd]C bond of the silyl enol ethers and subsequent base-induced elimination under mild conditions.

Synthesis of isoxazoles via cyclization of β-fluoro enones with sodium azide

A practical method for the synthesis of 3,5-disubstituted isoxazoles via cyclization of β-fluoro enones with sodium azide was disclosed. Density functional theory (DFT) calculation indicated that both (1) the azirine formation followed by intramolecular rearrangement and (2) direct enolate O-attack via 5-exo-trig cyclization of vinyl azide were possible for the isoxazole formation.

Design and Synthesis of Novel Arylisoxazole-Chromenone Carboxamides: Investigation of Biological Activities Associated with Alzheimer's Disease

A novel series of hybrid arylisoxazole-chromenone carboxamides were designed, synthesized, and evaluated for their cholinesterase (ChE) inhibitory activity based on the modified Ellman's method. Among synthesized compounds, 5-(3-nitrophenyl)-N-{4-[(2-oxo-

Design, synthesis and structure-based optimization of novel isoxazole-containing benzamide derivatives as FtsZ modulators

Antibiotic resistance among clinically significant bacterial pathogens is becoming a prevalent threat to public health, and new antibacterial agents with novel mechanisms of action hence are in an urgent need. Utilizing computational docking method and structure-based optimization strategy, we rationally designed and synthesized two series of isoxazol-3-yl- and isoxazol-5-yl-containing benzamide derivatives that targeted the bacterial cell division protein FtsZ. Evaluation of their activity against a panel of Gram-positive and -negative pathogens revealed that compounds B14 and B16 that possessed the isoxazol-5-yl group showed strong antibacterial activity against various testing strains, including methicillin-resistant Staphylococcus aureus and penicillin-resistant S. aureus. Further molecular biological studies and docking analyses proved that the compound functioned as an effective inhibitor to alter the dynamics of FtsZ self-polymerization via a stimulatory mechanism, which finally terminated the cell division and caused cell death. Taken together, these results could suggest a promising chemotype for development of new FtsZ-targeting bactericidal agent.

Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists

Optimisation of a screening hit incorporating both TRPV1 activity and solubility was conducted. Substitution of the isoxazole-3-carboxamide with the bespoke 1S, 3R-3-aminocyclohexanol motif afforded the requisite balance of potency and solubility. Compounds 32 and 40 were found to have antihyperalgesic effects in the rat CFA Hg assay and induce a mechanism based hyperthermia.

Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa

New chloro-substituted biarylmethoxyphenyl piperidine-4-carboxamides were synthesized and assayed in vitro as inhibitors of the blood coagulation enzymes factor Xa (fXa) and thrombin. An investigation of effects of the amidine and isopropyl groups attache

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

NEW PROCESS FOR THE PREPARATION OF 1- [5- (3-CHLORO-PHENYL) - ISOOXAZOL-3-YL] -ETHANONE AND (R) -1- [5- (3-CHLORO-PHENYL) - ISOOXAZOL-3-YL] -ETHANOL

The present invention provides a process for the preparation of the compound 1- [5- (3-chloro-phenyl) -isooxazol-3-yl] - ethanone: Wherein the compound 5- (3-chlorophenyl) -isooxazol-3- carboxylate is reacted with CH3MgX. The present invention also provid

NOC chemistry for tuberculosis - Further investigations on the structure-activity relationships of antitubercular isoxazole-3-carboxylic acid ester derivatives

NOC, NOC! Who's there? We have expanded the body of structure-activity relationships (SAR) regarding the 3-isoxazolecarboxylic acid ethyl esters by the design and synthesis of 5-aryl- and 5-[(N-aryl)amino]methyl analogues. Compounds were active against Mycobacterium tuberculosis (Mtb) at sub-micromolar concentrations and, for selected compounds, no toxicity was observed on Vero cells.